PN Patsalos

980 total citations
32 papers, 699 citations indexed

About

PN Patsalos is a scholar working on Pediatrics, Perinatology and Child Health, Psychiatry and Mental health and Oncology. According to data from OpenAlex, PN Patsalos has authored 32 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pediatrics, Perinatology and Child Health, 21 papers in Psychiatry and Mental health and 6 papers in Oncology. Recurrent topics in PN Patsalos's work include Epilepsy research and treatment (21 papers), Pharmacological Effects and Toxicity Studies (20 papers) and Drug Transport and Resistance Mechanisms (5 papers). PN Patsalos is often cited by papers focused on Epilepsy research and treatment (21 papers), Pharmacological Effects and Toxicity Studies (20 papers) and Drug Transport and Resistance Mechanisms (5 papers). PN Patsalos collaborates with scholars based in United Kingdom, Italy and Australia. PN Patsalos's co-authors include Matthew C. Walker, Simon Shorvon, Josemir W. Sander, A.A. Elyas, John S. Duncan, Joanna M. Zakrzewska, Michael Orth, Y Hart, Neville Ratnaraj and Sigurlaug Sveinbjörnsdóttir and has published in prestigious journals such as The Lancet, Neurology and Pharmacology & Therapeutics.

In The Last Decade

PN Patsalos

32 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
PN Patsalos United Kingdom 15 426 385 197 91 85 32 699
G. J. A. Macphee United Kingdom 12 205 0.5× 198 0.5× 164 0.8× 347 3.8× 29 0.3× 24 746
I. Martínez Brazil 2 396 0.9× 238 0.6× 256 1.3× 62 0.7× 50 0.6× 2 584
Juan A. Armijo Spain 18 647 1.5× 631 1.6× 236 1.2× 25 0.3× 180 2.1× 53 971
Ronald C. Reed United States 17 569 1.3× 462 1.2× 190 1.0× 42 0.5× 48 0.6× 42 789
Roger Deaton United States 11 600 1.4× 252 0.7× 64 0.3× 35 0.4× 44 0.5× 11 914
Shichuo Li China 15 454 1.1× 345 0.9× 99 0.5× 71 0.8× 40 0.5× 30 738
G. Oteri Italy 16 752 1.8× 657 1.7× 209 1.1× 51 0.6× 127 1.5× 32 1.0k
Alexander Legge United States 9 406 1.0× 328 0.9× 182 0.9× 25 0.3× 26 0.3× 11 555
John O. Rarick United States 10 682 1.6× 476 1.2× 188 1.0× 52 0.6× 74 0.9× 14 828
Harold E. Booker United States 16 295 0.7× 282 0.7× 178 0.9× 40 0.4× 55 0.6× 32 670

Countries citing papers authored by PN Patsalos

Since Specialization
Citations

This map shows the geographic impact of PN Patsalos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PN Patsalos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PN Patsalos more than expected).

Fields of papers citing papers by PN Patsalos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by PN Patsalos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PN Patsalos. The network helps show where PN Patsalos may publish in the future.

Co-authorship network of co-authors of PN Patsalos

This figure shows the co-authorship network connecting the top 25 collaborators of PN Patsalos. A scholar is included among the top collaborators of PN Patsalos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PN Patsalos. PN Patsalos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sander, Josemir W., et al.. (2004). Double-blind placebo-controlled parallel-group trial of omega-3 fatty acid supplementation in patients with chronic epilepsy. UCL Discovery (University College London). 3 indexed citations
2.
Orth, Michael, Benedikt L. Amann, Neville Ratnaraj, PN Patsalos, & John C. Rothwell. (2004). Caffeine has no effect on measures of cortical excitability. Clinical Neurophysiology. 116(2). 308–314. 32 indexed citations
4.
Manson, Alice J., PN Patsalos, P D Carey, et al.. (2001). Intravenous apomorphine therapy in Parkinson's. 1 indexed citations
5.
Patsalos, PN. (2000). Anti-epileptic drugs: newly licensed and under development.. PubMed. 3(4). 416–29. 7 indexed citations
6.
Patsalos, PN. (1999). The pharmacokinetic profile of topiramate. UCL Discovery (University College London). 15 indexed citations
7.
Patsalos, PN, et al.. (1999). Concentration-related pharmacodynamic studies with vigabatrin and tiagabine in rat brain and eye.. UCL Discovery (University College London). 9 indexed citations
8.
Patsalos, PN. (1999). The mechanism of action of topiramate. UCL Discovery (University College London). 49 indexed citations
9.
NAGAKI, Shigeru, Neville Ratnaraj, & PN Patsalos. (1999). Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. European Journal of Drug Metabolism and Pharmacokinetics. 24(3). 255–264. 10 indexed citations
10.
Walker, Matthew C., Xinchun Tong, Steven Brown, Simon Shorvon, & PN Patsalos. (1998). Comparison of Single‐ and Repeated‐Dose Pharmacokinetics of Diazepam. Epilepsia. 39(3). 283–289. 31 indexed citations
11.
Walker, Matthew C. & PN Patsalos. (1996). The tolerability and safety profile of gabapentin. UCL Discovery (University College London). 6 indexed citations
12.
Walker, Matthew C. & PN Patsalos. (1995). Clinical pharmacokinetics of new antiepileptic drugs. Pharmacology & Therapeutics. 67(3). 351–384. 93 indexed citations
13.
Wenning, Gregor K., Mark T. O’Connell, PN Patsalos, & Niall Quinn. (1995). A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. Movement Disorders. 10(5). 664–667. 8 indexed citations
14.
Patsalos, PN & John S. Duncan. (1994). NEW ANTIEPILEPTIC DRUGS - A REVIEW OF THEIR CURRENT STATUS AND CLINICAL POTENTIAL. UCL Discovery (University College London). 14 indexed citations
15.
Alavijeh, Mohammad S., et al.. (1994). An evaluation of the epileptogenic properties of a rifampicin/clindamycin-impregnated shunt catheter. British Journal of Neurosurgery. 8(6). 725–730. 12 indexed citations
16.
Sveinbjörnsdóttir, Sigurlaug, Josemir W. Sander, PN Patsalos, et al.. (1994). Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure. 3(1). 29–35. 57 indexed citations
17.
Stocchi, Fabrizio, Niall Quinn, Luca Barbato, et al.. (1994). Comparison Between a Fast and a Slow Release Preparation of Levodopa and a Combination of the Two. Clinical Neuropharmacology. 17(1). 38–44. 45 indexed citations
18.
Dhillon, S., et al.. (1991). A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Research. 10(2-3). 183–190. 37 indexed citations
19.
Sander, Josemir W., et al.. (1990). The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Research. 7(3). 226–229. 63 indexed citations
20.
Patsalos, PN, Joanna M. Zakrzewska, & A.A. Elyas. (1990). Dose dependent enzyme induction by oxcarbazepine?. European Journal of Clinical Pharmacology. 39(2). 187–188. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026